Deferasirox-13C6

Deferasirox-13C6 (ICL 670-13C6) is 13C labeled Deferasirox. Deferasirox (ICL 670) is an orally available iron chelator used for the management of transfusional iron overload[1][2][3].

Product Specifications

CAS Number

[1261392-79-3]

Product Name Alternative

ICL 670-13C6

UNSPSC

12352005

Target

Bacterial; Ferroptosis; Isotope-Labeled Compounds

Related Pathways

Anti-infection; Apoptosis; Others

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

OC1=C(C=CC=C1)C2=NC(C3=C(C=CC=C3)O)=NN2[13C]4=[13CH][13CH]=[13C]([13CH]=[13CH]4)C(O)=O

Molecular Formula

C15 13C6H15N3O4

Molecular Weight

379.32

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Sobbe A, et al. Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox. J Gastroenterol Hepatol. 2015 Mar;30 (3) :638-45.|[3]Kim JL, et al. The oral iron chelator deferasirox induces apoptosis in myeloid leukemia cells by targetingcaspase. Acta Haematol. 2011;126 (4) :241-5.|[4]Lee DH, et al. Deferasirox shows in vitro and in vivo antileukemic effects on murine leukemic cell lines regardless of iron status. Exp Hematol. 2013 Jun;41 (6) :539-46.